← Evidence map

ReviewHormones (Athens, Greece)2026

Dual target, dual benefit: real-world effects of SGLT2 inhibitors and GLP-1 receptor agonists on the FIB-4 score in people with type 2 diabetes mellitus.

Virginia Markoutsaki et al.PubMed ↗Publisher ↗

No numbers read from the abstract.

1 paper cites it

2026

this papertrialcites it

Dual target, dual benefit: real-world effects of SGLT2 inhibitors and GLP-1 receptor agonists on the FIB-4 score in people with type 2 diabetes mellitus. | OpenQuestion